Cargando…

The Transaxillary Route as a Second Access Option in TAVI Procedures: Experience of a Single Centre

Background: The aim of our study was to determine the feasibility and efficacy of transaxillary (TAX) TAVI in patients not eligible for the transfemoral route. Methods: This is a retrospective study of a single center. We analysed 262 patients treated with TAVI. In 17 patients (6.5%), the procedure...

Descripción completa

Detalles Bibliográficos
Autores principales: Muscoli, Saverio, Cammalleri, Valeria, Bonanni, Michela, Prandi, Francesca Romana, Sanseviero, Angela, Massaro, Gianluca, Di Luozzo, Marco, Chiocchi, Marcello, Ascoli Marchetti, Andrea, Ippoliti, Arnaldo, Zingaro, Alessia, Ussia, Gian Paolo, Romeo, Francesco, De Vico, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323695/
https://www.ncbi.nlm.nih.gov/pubmed/35886501
http://dx.doi.org/10.3390/ijerph19148649
Descripción
Sumario:Background: The aim of our study was to determine the feasibility and efficacy of transaxillary (TAX) TAVI in patients not eligible for the transfemoral route. Methods: This is a retrospective study of a single center. We analysed 262 patients treated with TAVI. In 17 patients (6.5%), the procedure was performed with the TAX approach. Procedural and hospital data, 30-day safety, and clinical efficacy were assessed and compared between the transfemoral and TAX groups. Results: In the TAX groups, we found a higher prevalence of men (p = 0.001), smokers (p = 0.033), and previous strokes (p = 0.02). The EUROSCORE II was higher in the TAX group (p = 0.014). The success rate of the device was 100%. TAX was associated with a longer procedure time (p = 0.001) and shorter median device time (p = 0.034) in minutes. Patients treated with TAX had a longer hospital stay (p = 0.005) and higher overall bleeding rate (p = 0.001). Peripheral neurological complications were more frequent with TAX (p = 0.001), which almost completely resolved by 30 days. Conclusions: TAX TAVI is safe and effective and should be considered as a second choice when transfemoral TAVI is not feasible due to severe comorbidities.